Tirzepatide for PCOS weight loss: what the evidence says

What did @erikatakeszep actually say?

Honestly? Almost nothing medically substantive. The transcript captures what appears to be a brief, offhand moment: "You're not sick. No, no, in fact. Helen, I'm hungry and I wish I had a snack." That's it. The caption does the heavier lifting here, disclosing that she's using tirzepatide (Zepbound) for PCOS-related weight loss and that she hasn't told anyone except her husband. The video seems to be a slice-of-life moment, not a medical explainer. So there's no real medical claim to dissect from the spoken words themselves. What we can fact-check is the implied framing: that tirzepatide is a relevant tool for someone with PCOS, and the casual reference to hunger, which may or may not be connected to her GLP-1 use.

Does the science back up tirzepatide for PCOS?

The short answer is: it's promising, but not yet FDA-approved for PCOS specifically. Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). PCOS is frequently associated with insulin resistance and excess weight, and weight loss itself, by almost any mechanism, tends to improve PCOS symptoms. A 2023 trial published in The New England Journal of Medicine (Jastreboff et al., 2022, NEJM) showed tirzepatide produced up to 20.9% body weight reduction in adults with obesity, which is clinically relevant for PCOS patients where even 5-10% weight loss can restore ovulatory function (Kiddy et al., 1992, Clinical Endocrinology). There are no large randomized controlled trials yet specifically in PCOS populations for tirzepatide, though trials are underway. The hunger comment, "I'm hungry and I wish I had a snack," is also worth noting: GLP-1 medications suppress appetite, but they don't eliminate hunger entirely, particularly in early weeks of treatment or at lower doses.

What did they get wrong, or right?

There's nothing explicitly wrong here because there's barely a medical claim made. Credit where it's due: the creator is transparent about her diagnosis (PCOS), her medication (tirzepatide/Zepbound), and her personal situation. She's not overpromising results or claiming a cure. The hunger comment is actually quietly accurate. A common misconception is that GLP-1 medications make hunger disappear completely. They don't. Research from Wadden et al. (2021, NEJM) on semaglutide showed appetite suppression is real but partial, and individual response varies considerably. If anything, her candid "I'm hungry" moment pushes back against the social media narrative that these drugs are magic switches. The one area to flag is that the video category was labeled TRT, which is completely mismatched. Tirzepatide is not testosterone. This appears to be a metadata or tagging error, and viewers should not conflate GLP-1 therapy with testosterone replacement therapy.

What should you actually know?

If you have PCOS and you're curious about tirzepatide, here's the grounded version. PCOS affects roughly 8-13% of reproductive-age women globally (WHO estimate) and is the leading cause of anovulatory infertility. Insulin resistance plays a central role in many cases, which is partly why GLP-1 and GIP receptor agonists are being studied in this population. Tirzepatide is not approved by the FDA to treat PCOS itself. It is approved for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Whether PCOS qualifies as that condition is a clinical judgment your prescribing provider has to make. Compounded versions of tirzepatide exist and are not equivalent to the FDA-approved Zepbound formulation. Do not assume they are interchangeable. Talk to a licensed provider before starting any GLP-1 therapy, particularly if you have PCOS-related metabolic concerns, a history of thyroid issues, or are trying to conceive.